CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

Recruiting in Palo Alto (17 mi)

Jae Park, MD - MSK Leukemia Specialist ...

Overseen byJae Park, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma. Researchers will also evaluate if this study therapy is safe, and to look for the highest dose that causes few or mild side effects in participants.

Eligibility Criteria

Adults over 18 with certain types of B-cell lymphoma that haven't responded to or have returned after treatment, including chemotherapy. Participants must have adequate kidney, liver, and heart function, no active CNS disease or other cancers requiring therapy beyond observation or hormones (except skin cancer), and not be pregnant.

Inclusion Criteria

Patients need to have radiographically documented disease

My oxygen levels are 92% or higher without extra oxygen.

I am 18 years old or older.

See 3 more

Exclusion Criteria

My condition limits me to minimal physical activity.

I have an active brain or spinal cord disease.

My heart's pumping ability is below normal.

See 9 more

Treatment Details

Interventions

19(T2)28z1xx TRAC T cell (CAR T-cell Therapy)

Trial OverviewThe trial is testing the safety and effectiveness of a new CAR T cell therapy called 19(T2)28z1xx TRAC for relapsed/refractory B-cell lymphoma. It aims to find the highest dose with minimal side effects by monitoring participants' responses.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Participants with Diffuse Large B-Cell Lymphoma (DLBCL) and large B cell lymphomaExperimental Treatment1 Intervention

Participants have histologically confirmed DLBCL and large B cell lymphoma. Participants will be treated with escalating doses of modified T cells.